April 22, 2024

bio:cap europe 2026

bio:cap europe 2026

bio:cap europe

bio:cap is Europe’s Life Science & AI Investival with one clear mission:
connecting breakthrough science to the funding that turns ideas into impact.

We unite global investors, founders, and industry leaders to spotlight and back the most promising innovations emerging from European research. bio:cap transforms cutting-edge science into investable ventures and fast-tracks their journey from lab bench to market front.

Our goal?
to benefit patients and society and to help create a resilient and sustainable European bioeconomy.

What is an Investival?

An Investival combines the best of both worlds: investment and festival.

bio:cap blends the depth of a traditional investor conference with the energy, openness, and creativity of a festival. Expect inspiring keynotes, curated matchmaking, and deep-dive sessions by day – followed by relaxed networking and standout social events in the evening. bio:cap is more than just a conference – it’s where deals, ideas, and visions come to life in a whole new atmosphere.

09 – 11 June 2026
CityCube, Messe Berlin


BioRN members receive a 60 % discount for the first 100 Tickets and 10% discount on booth bookings (valid until March 31, 2026)

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Providing a cellular ‘all-clear’ signal to resume protein synthesis

Providing a cellular ‘all-clear’ signal to resume protein synthesis

Researchers’ newest technologies allow them to discover tiny protein that plays a big role in awakening dormant cells when it’s safe to resume normal operations Summary It’s a tough world for microbes. When resources grow limited and environments worsen, microbes have figured out ways to hunker down and go dormant until conditions improve. However, scientists […]

Scientists uncover thousands of new proteins in ‘dark proteome’

Scientists uncover thousands of new proteins in ‘dark proteome’

An international consortium has found over 1,700 new proteins from noncoding DNA, many of which show potential as targets for cancer immunotherapy In a collaborative effort, scientists in the TransCODE consortium reveal more than 1,700 new proteins that could have implications for human diseases, including cancer. These tiny proteins were found in what’s called the […]

The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp